COVID-19 and Lung Cancer: What We Know and Don’t Know
Researchers have summarized what is known about COVID-19 in the context of lung cancer and highlighted areas where more research is needed.
Researchers have summarized what is known about COVID-19 in the context of lung cancer and highlighted areas where more research is needed.
An update to active surveillance recommendations has some physicians concerned.
About 20% of pediatric cancer patients who developed COVID-19 had severe or critical disease.
Responses varied according to patients’ cancer type, the anticancer treatment they received, and which vaccine was used.
Integrating molecular profiling into current clinical stratification could improve outcomes in rhabdomyosarcoma, according to researchers.
Children treated for neuroblastoma developed myeloid neoplasms with specific platinum chemotherapy-associated mutation signatures.
A new review points to low rates of genetic testing in patients with ovarian cancer.
A 10% reduction in calorie intake during the first month of treatment shows promise for augmenting chemotherapy treatment in children and adolescents with ALL.
A comprehensive review provides clinical pearls and approaches to consider regarding chemoradiotherapy for patients with stage III non-small cell lung cancer.
Researchers hope their findings could lead to targeted interventions to improve cognitive outcomes in pediatric brain tumor survivors from families with low socioeconomic status.